|
CA2659344A1
|
|
Treatment and prevention of excessive scarring
|
|
EP1891945A1
|
|
Treatment and prevention of excessive scarring
|
|
BRPI0610454A2
|
|
Type 2 diabetes treatment or prevention method
|
|
HK1077512A1
|
|
Reduction of breast density with 4-hydroxy tamoxifen
|
|
EP1799201A1
|
|
4-hydroxy tamoxifen gel formulations
|
|
NZ553446A
|
|
Testosterone gels comprising propylene glycol as penetration enhancer
|
|
EP1694319A1
|
|
Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
|
|
EP1647271A1
|
|
4-Hydroxy tamoxifen gel formulations
|
|
EP1634583A1
|
|
Testosterone gels comprising propylene glycol as penetration enhancer
|
|
EP1579857A1
|
|
Chemically stable compositions of 4-hydroxy tamoxifen
|
|
EP1579856A1
|
|
Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
|
|
US2005209340A1
|
|
Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
|
|
AU2003296757A8
|
|
Reduction of breast density with 4-hydroxy tamoxifen
|
|
EP1550440A1
|
|
Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
|
|
FR2821555A1
|
|
Progestive co-micronized with a surfactant, pharmaceutical composition comprising same, methods of making same and uses thereof
|
|
EP0872240A1
|
|
Solid preparation from vitamins and calcium, its manufacturing process and use
|
